Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.7444
Abstract: This cohort study uses published clinical trial data to assess long-term survival of patients with metastatic urothelial carcinoma who are treated with immune checkpoint inhibitors. read more here.
Keywords: long term; immune checkpoint; metastatic urothelial; term survival ... See more keywords
Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13288
Abstract: The prognosis of metastatic urothelial carcinoma (mUC) patients is poor, and early prediction of systemic therapy response would be valuable to improve outcome. In this exploratory study, we investigated protein profiles in sequential plasma‐isolated extracellular… read more here.
Keywords: oncology; extracellular vesicles; metastatic urothelial; protein signatures ... See more keywords
Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "European Radiology"
DOI: 10.1007/s00330-020-06847-0
Abstract: Objectives To evaluate the usefulness of a radiomics-based prediction model for predicting response and survival outcomes of patients with metastatic urothelial carcinoma treated with immunotherapy targeting programmed cell death 1 (PD-1) and its ligand (PD-L1).… read more here.
Keywords: radiomics based; model; urothelial carcinoma; metastatic urothelial ... See more keywords
Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy – results of an exploratory phase I study
Sign Up to like & getrecommendations! Published in 2017 at "Investigational New Drugs"
DOI: 10.1007/s10637-017-0528-y
Abstract: SummaryVinflunine is to date the only registered agent for second-line treatment of metastatic urothelial cell carcinoma (UCC) in Europe. However, the effect is modest. Pemetrexed has demonstrated some single-agent activity in this disease entity. In… read more here.
Keywords: urothelial cell; cell carcinoma; treatment; vinflunine ... See more keywords
Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First‐Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta‐Analysis
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Genitourinary Cancer"
DOI: 10.1016/j.clgc.2016.05.003
Abstract: &NA; Although gemcitabine plus carboplatin (GCa) is the conventional first‐line chemotherapy for cisplatin‐ineligible metastatic urothelial carcinoma, its results are suboptimal. A meta‐analysis evaluated the results of gemcitabine with either carboplatin or a taxane (GT). Literature… read more here.
Keywords: first line; analysis; gca; gemcitabine plus ... See more keywords
Consolidative Radiotherapy in Metastatic Urothelial Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Genitourinary Cancer"
DOI: 10.1016/j.clgc.2017.04.007
Abstract: Micro‐Abstract We analyzed a group of 22 patients with metastatic urothelial carcinoma who had received consolidative radiation after chemotherapy. Patients who received consolidative radiotherapy achieved a 19‐month progression‐free survival and 49‐month overall, with 36% of… read more here.
Keywords: chemotherapy; consolidative radiotherapy; disease free; metastatic urothelial ... See more keywords
Metastatic urothelial carcinoma to the liver with unknown primary tumor
Sign Up to like & getrecommendations! Published in 2019 at "Urology Case Reports"
DOI: 10.1016/j.eucr.2019.100993
Abstract: Cancer of unknown primary (CUP), a rare and aggressive clinical entity, accounts for approximately 3% of all malignancies. CUP with urothelial origin is even more unusual, with no other cases reported in the current literature.… read more here.
Keywords: carcinoma liver; primary tumor; unknown primary; urothelial carcinoma ... See more keywords
Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study.
Sign Up to like & getrecommendations! Published in 2021 at "European urology focus"
DOI: 10.1016/j.euf.2021.03.005
Abstract: BACKGROUND Patients with metastatic urothelial carcinoma (mUC) have poor prognosis, so further development of novel combinations for these patients is needed. OBJECTIVE To assess the safety and efficacy of eribulin mesylate (eribulin) with avelumab in… read more here.
Keywords: combination; study; urothelial carcinoma; metastatic urothelial ... See more keywords
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer.
Sign Up to like & getrecommendations! Published in 2021 at "European urology oncology"
DOI: 10.1016/j.euo.2021.10.006
Abstract: Deficiency of MTAP (MTAPdef) mainly occurs because of homozygous loss of chromosome 9p21, which is the most common copy-number loss in metastatic urothelial cancer (mUC). We characterized the clinical and genomic features of MTAPdef mUC… read more here.
Keywords: urothelial cancer; mtap; biology; cancer ... See more keywords
Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2017.03.047
Abstract: Immune checkpoint inhibitors are a new treatment option in metastatic urothelial cancer on the basis of available phase 2 and 3 trials. Predictive biomarkers are needed. These should go beyond PD-L1 expression, which is showing… read more here.
Keywords: checkpoint inhibition; immune checkpoint; metastatic urothelial; urothelial cancer ... See more keywords
Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/nrclinonc.2017.184
Abstract: 2017 saw the publication of clinical trial data and the approval of new treatment approaches for metastatic urothelial carcinoma. Pembrolizumab is now a well-established treatment for patients with disease progression after cisplatin, with high-level evidence… read more here.
Keywords: urothelial cancer; cancer 2017; urothelial carcinoma; 2017 changes ... See more keywords